Pfizer 2005 Annual Report Download - page 72

Download and view the complete annual report

Please find page 72 of the 2005 Pfizer annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 75

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75

2005 Financial Report 71
QUARTER
(MILLIONS OF DOLLARS, EXCEPT PER COMMON SHARE DATA) FIRST SECOND THIRD FOURTH
2005
Revenues $13,091 $12,425 $12,189 $13,592
Costs and expenses 9,960 8,834 8,295 9,631
Merger-related in-process research and development charges 2260 1,390 —
Restructuring charges and merger-related costs 219 270 307 596
Income from continuing operations before provision for taxes
on income, and minority interests 2,910 3,061 2,197 3,365
Provision/(benefit) for taxes on income 2,635 (413) 591 610
Minority interests 3247
Income from continuing operations 272 3,472 1,602 2,748
Discontinued operations:
(Loss) income from discontinued operations—net of tax (12) (9) (16) 6
Gains on sales of discontinued operations—net of tax 41 — 3 3
Discontinued operations—net of tax 29 (9) (13) 9
Cumulative effect of a change in accounting principles ———(25)
Net income $301 $ 3,463 $ 1,589 $ 2,732
Earnings per common share—basic:
Income from continuing operations $0.04 $ 0.47 $ 0.22 $ 0.37
Discontinued operations—net of tax ————
Cumulative effect of a change in accounting principles ————
Net income $0.04 $ 0.47 $ 0.22 $ 0.37
Earnings per common share—diluted:
Income from continuing operations $0.04 $ 0.47 $ 0.22 $ 0.37
Discontinued operations—net of tax ————
Cumulative effect of a change in accounting principles ————
Net income $0.04 $ 0.47 $ 0.22 $ 0.37
Cash dividends paid per common share $0.19 $ 0.19 $ 0.19 $ 0.19
Stock prices
High $27.75 $ 29.21 $ 27.82 $ 25.57
Low $23.80 $ 25.52 $ 24.67 $ 20.27
Quarterly Consolidated Financial Data (Unaudited)
Pfizer Inc and Subsidiary Companies
Merger-related in-process research and development charges
primarily includes amounts incurred in connection with our
acquisition of Vicuron and Idun (see Note 2B, Acquisitions: Other
Acquisitions).
Restructuring charges and merger-related costs include
integration and restructuring costs primarily related to our
acquisition of Pharmacia (see Note 5, Merger-Related Costs) and
the restructuring charges related to our AtS initiative (see Note 4,
Adapting to Scale Initiative).
As of January 31, 2006, there were 254,564 record holders of our
common stock (symbol PFE).